R
Recombinant Factor VIII
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Standard Drug List
Active ingredients: Coagulation Factor VIII (Recombinant) | Recombinant Factor VIII Synonyms: Antihemophilic Factor (Recombinant) | Lonoctocog Alfa [INN] | Moroctocog Alfa [INN/BAN] | Octocog Alfa [INN] | Simoctocog Alfa [INN] | Turoctocog Alfa [INN]
General information
Subsidy Information and Financing Scheme
[SDL] Recombinant factor VIII (Moroctocog alfa) [Xyntha] Injection, 250 international units, 500 international units, 1,000 international units, 2,000 international units
[SDL] Recombinant factor VIII (Octocog alfa) [Advate] Injection, 250 international units, 500 international units, 1,000 international units, 1,500 international units
Drug Guidance for Subsidy
19/12/2022 Recombinant blood products for prophylaxis and management of haemophilia A and B>
[R] The Ministry of Health’s Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:
Octocog alfa (Advate) 250 international units, 500 international units, 1000 international units and 1500 international units powder and solvent for solution for injection
Rurioctocog alfa pegol (Adynovate) 250 international units, 500 international units, 1000 international units, 1500 international units, 2000 international units and 3000 international units powder and solvent for solution for injection
Nonacog alfa (BeneFIX) 250 international units, 500 international units, 1000 international units and 2000 international units powder and solvent for solution for injection
[NR] Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.
The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Xyntha Injection 250 international units |
|
Xyntha Injection 500 international units |
|
Advate Injection 250 international units |
|
Advate Injection 500 international units |
|
Advate Injection 1,000 international units |
|
List of monographs containing this active ingredient
Recombinant Factor VIII [Afstyla]
Recombinant Factor VIII [NovoEight]
Recombinant Factor VIII [Nuwiq]